<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2252">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04370119</url>
  </required_header>
  <id_info>
    <org_study_id>BB 068/20</org_study_id>
    <nct_id>NCT04370119</nct_id>
  </id_info>
  <brief_title>Screening for SARS-CoV-2-Infections and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers</brief_title>
  <acronym>SeCo</acronym>
  <official_title>Screening for SARS-CoV-2-Infections and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medicine Greifswald</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Friedrich Loefler Institute for Animal Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EUROIMMUN AG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medicine Greifswald</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives of this study are 1) to establish the prevalence of SARS-CoV-2 in
      asymptomatic healthcare workers (HCWs) in an early phase of community spread as well as 2) to
      monitor the future spread of the disease by assessing serological responses to SARS-CoV-2 in
      symptomatic and asymptomatic HCWs over time and 3) to improve the assessment of the immune
      response and its protective effect as well as the assessment of infectivity of affected HCWs
      and 4) to evaluate the value and significance of antibody formation and serological antibody
      tests and 5) to be able to evaluate possible future preventive and / or therapeutic
      approaches against SARS-CoV-2
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to collect information on staff working at the Greifswald University
      hospital.

      Over a 5 year period, 6 study visits per participant are planned. At each visit, nasal/throat
      swabs (for PCR testing) and/or blood samples (for SARS-CoV-2 antibody testing) will be
      collected. This will help to gain a better understanding of viral load and antibody
      development over time.

      The remaining blood samples will be stored in a repository for future research.

      The study is part of a modular SARS-CoV-2-research programme of the University Medicine
      Greifswald.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2020</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of people with detectable antibodies to SARS-COV2</measure>
    <time_frame>1 year</time_frame>
    <description>Anti-SARS-COV2 S protein IgG ELISA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of people with detectable SARS-COV2 nucleic acid</measure>
    <time_frame>1 year</time_frame>
    <description>SARS-COV2 PCR</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of people with detectable antibodies to SARS-COV2</measure>
    <time_frame>2 years</time_frame>
    <description>Anti-SARS-COV2 S protein IgG ELISA</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of people with detectable antibodies to SARS-COV2</measure>
    <time_frame>3 years</time_frame>
    <description>Anti-SARS-COV2 S protein IgG ELISA</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of people with detectable antibodies to SARS-COV2</measure>
    <time_frame>4 years</time_frame>
    <description>Anti-SARS-COV2 S protein IgG ELISA</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of people with detectable antibodies to SARS-COV2</measure>
    <time_frame>5 years</time_frame>
    <description>Anti-SARS-COV2 S protein IgG ELISA</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of people with detectable SARS-COV2 nucleic acid</measure>
    <time_frame>2 years</time_frame>
    <description>SARS-COV2 PCR</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of people with detectable SARS-COV2 nucleic acid</measure>
    <time_frame>3 years</time_frame>
    <description>SARS-COV2 PCR</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of people with detectable SARS-COV2 nucleic acid</measure>
    <time_frame>4 years</time_frame>
    <description>SARS-COV2 PCR</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of people with detectable SARS-COV2 nucleic acid</measure>
    <time_frame>5 years</time_frame>
    <description>SARS-COV2 PCR</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>SARS-Cov-2</condition>
  <arm_group>
    <arm_group_label>Healthcare workers</arm_group_label>
    <description>Healthcare workers at University Medicine Greifswald</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Nasal swab</intervention_name>
    <description>SARS-CoV-2 PCR</description>
    <arm_group_label>Healthcare workers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serum testing</intervention_name>
    <description>Anti-SARS-CoV2 S protein IgG ELISA</description>
    <arm_group_label>Healthcare workers</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, nasal/throat swabs
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Health Care Worker
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. &gt;= 18 years of age

          2. Willing and able to complete a written consent form

          3. Willing to have blood samples stored for future research

          4. Healthcare worker employed at Greifswald University Hospital

        Exclusion Criteria:

          1. &lt; 18 years of age

          2. Decline to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nils-Olaf Hübner, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medicine Greifswald</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karsten Becker, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medicine Greifswald</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nils-Olaf Hübner, Prof.Dr.</last_name>
    <phone>03834-86-4833</phone>
    <email>nils.huebner@med.uni-greifswald.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lena Ulm, Dr.</last_name>
    <phone>03834-86-5584</phone>
    <email>lena.ulm@med.uni-greifswald.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Greifswald University Medicine</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nils-Olaf Hübner, Prof.Dr.</last_name>
      <phone>03834-86-4833</phone>
      <email>nils.huebner@med.uni-greifswald.de</email>
    </contact>
    <contact_backup>
      <last_name>Lena Ulm, Dr.</last_name>
      <phone>03834 - 86 5584</phone>
      <email>lena.ulm@med.uni-greifswald.de</email>
    </contact_backup>
    <investigator>
      <last_name>Nils-Olaf Hübner, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karsten Becker, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Rutscher, Dipl.-Med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicole Endlich, Prof.Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Greinacher, Prof.Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Nauck, Prof.Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mladen V. Tzvetkov, Prof.Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henry Völzke, Prof.Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marek Zygmunt, Prof.Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Beer, Prof.Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Groschup, Prof.Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas C. Mettenleiter, Prof.Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wolfgang Schlumberger, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Serology</keyword>
  <keyword>antibody formation</keyword>
  <keyword>epidemiology</keyword>
  <keyword>immunity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

